Paraoxonase 1 Activity in Patients with Chronic Obstructive Pulmonary Disease

Rumora, Lada; Rajković, Marija Grdić; Kopcinovic, Lara Milevoj; Pancirov, Dolores; Čepelak, Ivana; Grubišić, Tihana Žanić

doi:10.3109/15412555.2014.898028

Cited by 17 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oxidative stress has important role in pathogenesis of COPD 23. In accordance with previously published papers we have demonstrated reduced paraoxonase and arylesterase PON1 activity in patients with COPD 27. The underlying mechanism that leads to the observed reduction of PON1 activity is not yet resolved.…”

Section: Discussionsupporting

confidence: 71%

“…In previously conducted study27 we found decreased PON1 paraoxonase and arylesterase activity in patients with COPD.…”

Section: Introductionmentioning

confidence: 67%

“…We have found previously that POX and POX1 as well as ARE were reduced in patients with COPD compared with the control group 27. In this study, we have compared both controls and patients according to their specific PON1 genotypes and PON1 activities (tables 6 and 7).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

PON1gene polymorphisms in patients with chronic obstructive pulmonary disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 71%

“…In previously conducted study27 we found decreased PON1 paraoxonase and arylesterase activity in patients with COPD.…”

Section: Introductionmentioning

confidence: 67%

See 1 more Smart Citation

PON1gene polymorphisms in patients with chronic obstructive pulmonary disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Además, Agler et al 47 , en un estudio de seguimiento de 10 años con 38.597 mujeres (≥45 años) encontraron que la suplementación con antioxidantes redujo el riesgo de desarrollar enfermedad pulmonar crónica en un 10% (HR 0,90; IC del 95%: 0,81 a 0,99; p = 0,029), adicionalmente se asoció con una disminución de los niveles de estrés carbonilo en el pulmón. Los estudios en individuos con EPOC demostraron una reducción en la actividad antioxidante de la superóxido dismutasa (SOD), catalasa (CAT), proteínas sulfhidrilas totales (SH), paraoxonasa 1 (PON1), glutatión peroxidasa y glutatión-Stransferasa (GST) [48][49][50][51] . Sin embargo, hay resultados contradictorios con algunos biomarcadores antioxidantes, como SH, superóxido dismutasa y catalasa, que han demostrado un aumento o no diferencias, en comparación con los individuos sin la EPOC 52,53 .…”

Section: Relación Entre El Estrés Oxidativo Y La Sarcopeniaunclassified

“…Los sujetos con EPOC tienen un desequilibrio entre los niveles de oxidantes y antioxidantes [48][49][50] . Los niveles de biomarcadores oxidantes están aumentados en individuos con EPOC [48][49][50][51][52][53][54][55][56] . La peroxidación lipídica y la oxidación de proteínas son consecuencias del estrés oxidativo y causan daño oxidativo 50,52,57,58 .…”

Section: Relación Entre El Estrés Oxidativo Y La Sarcopeniaunclassified

Mecanismos fisiopatológicos de la sarcopenia en la EPOC

Sepúlveda-Loyola

Sérgio

Probst

2019

Rev. chil. enferm. respir.

View full text Add to dashboard Cite

Mecanismos fisiopatológicos de la sarcopenia en la EPOC Pathophysiological mechanism of sarcopenia in COPDSarcopenia is a disease characterized by loss of skeletal muscle, muscle strength and physical performance, being the major cause of frailty in the elderly. The sarcopenia is highly prevalent in individuals with Chronic obstructive pulmonary disease (COPD) leading to a poor prognosis and higher mortality in this population. The presence of sarcopenia in COPD is likely the result by the interaction between external and internal factors as systemic inflammation, oxidative stress and genetic polymorphisms, frequently observed in individuals with this respiratory disease. This review summarizes the current knowledge about the pathogenic mechanisms linking COPD with sarcopenia.

show abstract

Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta‐analysis

Sepúlveda-Loyola

Osadnik

Phu

et al. 2020

J cachexia sarcopenia muscle

129

109

View full text Add to dashboard Cite

Sarcopenia prevalence and its clinical impact are reportedly variable in chronic obstructive pulmonary disease (COPD) due partly to definition criteria. This review aimed to identify the criteria used to diagnose sarcopenia and the prevalence and impact of sarcopenia on health outcomes in people with COPD. This review was registered in PROSPERO (CRD42018092576). Five electronic databases were searched to August 2018 to identify studies related to sarcopenia and COPD. Study quality was assessed using validated instruments matched to study designs. Sarcopenia prevalence was determined using authors' definitions. Comparisons were made between people who did and did not have sarcopenia for pulmonary function, exercise capacity, quality of life, muscle strength, gait speed, physical activity levels, inflammation/oxidative stress, and mortality. Twenty-three studies (70% cross-sectional) from Europe (10), Asia (9), and North and South America (4) involving 9637 participants aged ≥40 years were included (69.5% men). Sarcopenia criteria were typically concordant with recommendations of hEuropean and Asian consensus bodies. Overall sarcopenia prevalence varied from 15.5% [95% confidence interval (CI) 11.8-19.1; combined muscle mass, strength, and/or physical performance criteria] to 34% (95%CI 20.6-47.3; muscle mass criteria alone) (P = 0.009 between subgroups) and was greater in people with more severe [37.6% (95%CI 24.8-50.4)] versus less severe [19.1% (95%CI 10.2-28.0)] lung disease (P = 0.020), but similar between men [41.0% (95%CI 26.2-55.9%)] and women [31.9% (95%CI 7.0-56.8%)] (P = 0.538). People with sarcopenia had lower predicted forced expiratory volume in the first second (mean difference À7.1%; 95%CI À9.0 to À5.1%) and poorer exercise tolerance (standardized mean difference À0.8; 95%CI À1.4 to À0.2) and quality of life (standardized mean difference 0.26; 95%CI 0.2-0.4) compared with those who did not (P < 0.001 for all). No clear relationship was observed between sarcopenia and inflammatory or oxidative stress biomarkers. Incident mortality was unreported in the literature. Sarcopenia is prevalent in a significant proportion of people with COPD and negatively impacts upon important clinical outcomes. Opportunities exist to optimize its early detection and management and to evaluate its impact on mortality in this patient group.

show abstract

Paraoxonase 1 Activity in Patients with Chronic Obstructive Pulmonary Disease

Cited by 17 publications

References 45 publications

PON1gene polymorphisms in patients with chronic obstructive pulmonary disease

PON1gene polymorphisms in patients with chronic obstructive pulmonary disease

Mecanismos fisiopatológicos de la sarcopenia en la EPOC

Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta‐analysis

Contact Info

Product

Resources

About